ArriVent to unveil first‑in‑human results for CDH17‑targeted ADC ARR‑217 at ESMO
ArriVent BioPharma said its initial safety and efficacy findings from the Phase 1 study of the CDH17‑directed antibody‑drug conjugate ARR‑217 will be shown in a late‑breaking oral session at the European Society for Medical Oncology Congress in Madrid. The company will follow the presentation with a virtual briefing on 26 October 2026 at 8 a.m. Eastern Time. The trial, registered as NCT07066657, enrolled 123 patients with gastrointestinal cancers and reported an objective response rate of 44.8 % at the 6 mg/kg dose. ArriVent plans to move the program into a Phase 1b dose‑optimization study, targeting 5–6 mg/kg every three weeks, with further data expected in 2027.
Why it matters
The disclosed response rate and safety profile give investors early insight into the drug’s potential, which could influence AVBP’s valuation ahead of later‑stage trials. The upcoming webinar provides a venue for analysts to ask detailed questions, possibly affecting short‑term trading activity.
Key facts
- 1The oral presentation is scheduled for Sunday, 25 October 2026 from 8:30 to 10:00 a.m. CEST (LBA34). stocktitan.net
- 2ArriVent will host a virtual webinar on Monday, 26 October 2026 at 8 a.m. ET to discuss the data. stocktitan.net
- 3The Phase 1 study is identified by clinical trial number NCT07066657. investing.com
- 4The trial included 123 patients with gastrointestinal malignancies. investing.com
- 5An objective response rate of 44.8 % was observed at the 6 mg/kg dose level. investing.com
- 6ArriVent obtained exclusive worldwide rights outside Greater China through a collaboration with Lepu Biopharma. investing.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.